Skip to main content

Oncology Precision Medicine Market Technological Advancement and Growth Analysis with Forecast to 2031


 

Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, the public investment led to the evolution of the personalization of disease-based therapies. The precision medicine concept is a systematic process aiming to achieve victory over a disease such as cancer. Cancer is the major focus of various precision medicine initiatives, and precision oncology centers around matching the most accurate and precise treatment to each cancer patient on the basis of an individual’s matching genetic profile that could ultimately let them benefit from the treatment offered.

The global  oncology precision medicine market  was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.

Factors fueling the growth of the market include increasing incidence of cancer globally, decreasing trial and error-based drug prescription through pharmacogenomics, increasing usage of predictive biomarkers for cancer diagnostics, and rapid technological advancements related to oncology precision medicine. 

Oncology Precision Medicine Market: Segmentation

The market is segmented between Ecosystem and Application, further it is segmented by Regions.

Market Segmentation

•    Ecosystem - Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics

•    Application - Solid Tumor and Hematological Malignancies

Regional Segmentation

•    North America: U.S., Canada

•    Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe

•    Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific

•    Latin America: Brazil, Mexico, and Rest-of-Latin America

•    Rest-of-the-World

Competitive Landscape

The exponential rise in the prevalence of cancer globally has created a buzz among companies to invest in oncology precision medicine.

Based on region, North America holds the largest share, owing to rising cancer prevalence and improvised regulatory policies pertaining to precision oncology in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.

Global Oncology Precision Medicine Market, Market Dynamics

Key Companies Profiled

Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN, Thermo Fisher Scientific Inc., BGI Group, ASURAGEN, INC., Almac Group Ltd., MDxHealth, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics Incorporated, Novartis AG

Key Questions Answered in this Report:

• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the major market drivers, restraints, and opportunities in the global oncology precision medicine market?
• What are the underlying structures resulting in the emerging trends within the global oncology precision medicine market?
• How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for oncology precision medicine?
• Who are the leading players with significant offerings to the global oncology precision medicine market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which ecosystem in the oncology precision medicine type has the most promising growth?
• What are the best applications employed in the global oncology precision medicine market? Which is the dominating application?
• Who are the key manufacturers in the global oncology precision medicine market, and what are their contributions? Also, what is the growth potential of each major oncology precision medicine manufacturer?
• What is the scope of the global oncology precision medicine market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which oncology precision medicine technology and end user dominate these regions?
• What are the emerging trends in the global oncology precision medicine market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the oncology precision medicine regimen?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the regulatory procedures that are required to unify the approval process for the emerging oncology precision medicine market? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing oncology precision medicine adoption in regular healthcare routines? How are these gaps being tackled?

Request Sample -  https://bisresearch.com/requestsample?id=1270type=download

Within the research report, the market has been segmented based on ecosystem, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

BIS Related Studies

Precision Cardiology Market - A Global and Regional Analysis

Global Precision Medicine Market

Comments

Popular posts from this blog

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: •     Industry Analysis    ...

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Hyperspectral Imaging Market Projections , Upcoming Trends Focus on Long-Term Impact of Covid-19 and Forecast By 2027

  The global  hyperspectral imaging market  was estimated to be at $791.2 million in 2021, which is expected to grow with a CAGR of 13.17% and reach $1,640.3 million by 2027.The growth in the global hyperspectral imaging market is expected to be primarily driven by increased awareness of the technology in different sectors such as agriculture, healthcare, and mining. The hyperspectral imaging technology has great potential, and the market is anticipated to grow during the forecast period owing to the widespread applications of HSI, increasing investments for RD activities, increasing demand from military and defense sectors, increased food safety concerns, and increasing awareness regarding early diagnosis of diseases.   COVID-19 Impact and Post-COVID-19 Scenario The COVID-19 pandemic had a debilitating impact on the global ecosystem. The pandemic led to a shutdown of production facilities, which do not come under essential goods, which led to a negative impact on se...